Market Overview

BioCardia Completes Roll-in Cohort in Pivotal Phase III CardiAMP Heart Failure Trial


(OTC:BCDA), a leader in the development of comprehensive
solutions for cardiovascular regenerative therapies, today announced
completion of treatment for the 10-patient roll-in cohort for the
pivotal Phase III CardiAMP Heart Failure Trial. A pre-specified review
of the 30-day outcomes in this cohort by the Data Safety Monitoring
Board is anticipated in the third quarter of 2017.

The investigational CardiAMP cell therapy system is designed to deliver
a high dose of a patient's own bone marrow cells directly to the region
of cardiac dysfunction to stimulate the body's natural healing mechanism
after a heart attack. Patients are selected for the investigational
treatment, in part, based on biomarkers in their bone marrow that are
anticipated to maximize the potential for patient benefit.

"Leading clinical sites are actively screening patients for the
randomized phase of our Phase III trial, and we are onboarding
additional clinical sites in the United States," stated BioCardia Chief
Medical Officer Eric Duckers, MD, PhD, FESC. "The company anticipates
filing an investigational device exemption (IDE) supplement to add an
interim efficacy readout in the fourth quarter of 2018 and expects top
line data in the fourth quarter of 2019."

The CardiAMP Heart Failure Trial is a Phase III, multi-center,
randomized, double-blinded, sham-controlled study of up to 260 patients
at 40 centers nationwide, which includes a 10-patient roll-in cohort.
The trial's primary endpoint is an improvement in six minute walking
distance at 12 months post-treatment. In addition, the primary endpoint
analysis incorporates the impact of major adverse cardiac events and
other clinically meaningful events.

The company reaffirms guidance on its IDE submission in calendar year
2017 for a new CardiAMP indication to treat patients post-myocardial
infarction. In addition, the company anticipates submitting an
investigational new drug (IND) application in calendar year 2018 for CardiALLO
cell therapy
, which utilizes bone marrow-derived mesenchymal cells
from a donor to treat heart failure.

About BioCardia®

BioCardia, Inc., headquartered in San Carlos, CA, is developing
regenerative biologic therapies to treat cardiovascular disease.
CardiAMP® and CardiALLO® cell therapies are the company's biotherapeutic
product candidates in clinical development. For more information, visit

Forward Looking Statements:

This press release contains forward-looking statements that are subject
to many risks and uncertainties. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations. Such factors include, among others,
the inherent uncertainties associated with developing new products or
technologies, unexpected expenditures, the ability to raise the
additional funding needed to continue to pursue BioCardia's business and
product development plans and overall market conditions. These
forward-looking statements are made as of the date of this press
release, and BioCardia assumes no obligation to update the
forward-looking statements.

We may use terms such as "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," "approximately" or other words that convey uncertainty of
future events or outcomes to identify these forward-looking statements.
Although we believe that we have a reasonable basis for each
forward-looking statement contained herein, we caution you that
forward-looking statements are not guarantees of future performance and
that our actual results of operations, financial condition and
liquidity, and the development of the industry in which we operate may
differ materially from the forward-looking statements contained in this
presentation. As a result of these factors, we cannot assure you that
the forward-looking statements in this presentation will prove to be
accurate. Additional factors that could materially affect actual results
can be found in BioCardia's Form 10-K filed with the Securities and
Exchange Commission on March 30, 2017, including under the caption
titled "Risk Factors." BioCardia expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.

View Comments and Join the Discussion!